CN106103450B - 作为磷酸肌醇3-激酶抑制剂的三环杂环化合物 - Google Patents

作为磷酸肌醇3-激酶抑制剂的三环杂环化合物 Download PDF

Info

Publication number
CN106103450B
CN106103450B CN201580008209.5A CN201580008209A CN106103450B CN 106103450 B CN106103450 B CN 106103450B CN 201580008209 A CN201580008209 A CN 201580008209A CN 106103450 B CN106103450 B CN 106103450B
Authority
CN
China
Prior art keywords
alkyl
compound
amino
carbonyl
sulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580008209.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN106103450A (zh
Inventor
斯蒂芬·约瑟夫·沙特勒沃斯
亚历山大·理查德·利亚姆·塞西尔
弗兰克·亚历山德勒·希尔瓦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fukang Shanghai Health Technology Co ltd
Original Assignee
Karus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karus Therapeutics Ltd filed Critical Karus Therapeutics Ltd
Publication of CN106103450A publication Critical patent/CN106103450A/zh
Application granted granted Critical
Publication of CN106103450B publication Critical patent/CN106103450B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201580008209.5A 2014-02-12 2015-02-12 作为磷酸肌醇3-激酶抑制剂的三环杂环化合物 Active CN106103450B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1402431.9A GB201402431D0 (en) 2014-02-12 2014-02-12 Compounds
GB1402431.9 2014-02-12
PCT/GB2015/050396 WO2015121657A1 (en) 2014-02-12 2015-02-12 Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors

Publications (2)

Publication Number Publication Date
CN106103450A CN106103450A (zh) 2016-11-09
CN106103450B true CN106103450B (zh) 2018-12-11

Family

ID=50390862

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580008209.5A Active CN106103450B (zh) 2014-02-12 2015-02-12 作为磷酸肌醇3-激酶抑制剂的三环杂环化合物

Country Status (28)

Country Link
US (4) US9981987B2 (enExample)
EP (1) EP3105233B1 (enExample)
JP (1) JP6516371B2 (enExample)
KR (1) KR102491796B1 (enExample)
CN (1) CN106103450B (enExample)
AU (1) AU2015216702B2 (enExample)
BR (1) BR112016019462B8 (enExample)
CA (1) CA2939045C (enExample)
CY (1) CY1120325T1 (enExample)
DK (1) DK3105233T3 (enExample)
ES (1) ES2673278T3 (enExample)
GB (1) GB201402431D0 (enExample)
HR (1) HRP20180768T1 (enExample)
HU (1) HUE037210T2 (enExample)
IL (1) IL247103B (enExample)
LT (1) LT3105233T (enExample)
MX (1) MX370151B (enExample)
NO (1) NO3105233T3 (enExample)
NZ (1) NZ723502A (enExample)
PL (1) PL3105233T3 (enExample)
PT (1) PT3105233T (enExample)
RS (1) RS57296B1 (enExample)
SG (1) SG11201606576UA (enExample)
SI (1) SI3105233T1 (enExample)
SM (1) SMT201800280T1 (enExample)
TR (1) TR201807906T4 (enExample)
WO (1) WO2015121657A1 (enExample)
ZA (1) ZA201605586B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2534326T3 (es) 2009-08-20 2015-04-21 Karus Therapeutics Limited Compuestos tricíclicos heterocíclicos como inhibidores de la fosfoinositida 3-cinasa
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
MX364295B (es) 2012-11-07 2019-04-22 Karus Therapeutics Ltd Inhibidores de histona desacetilasa novedosos y su uso en terapia.
PL2994465T3 (pl) 2013-05-10 2019-01-31 Karus Therapeutics Limited Nowe inhibitory deacetylazy histonowej
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201419228D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201419264D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201514758D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514760D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514756D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compound and method of use
GB201514754D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201909468D0 (en) * 2019-07-01 2019-08-14 Karus Therapeutics Ltd Compounds for treating cancer
WO2021113633A1 (en) 2019-12-05 2021-06-10 Verge Analytics, Inc. Fused tricyclic heterocyclic compounds as inhibitors of pikfyve kinase useful for the treatment of neurological diseases
WO2022169882A1 (en) 2021-02-03 2022-08-11 Verge Analytics, Inc. Methods and treatment of viral infection caused by sars-cov-2

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010052569A2 (en) * 2008-11-10 2010-05-14 University Of Basel Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes
CN102498115A (zh) * 2009-08-20 2012-06-13 卡鲁斯治疗有限公司 作为磷酸肌醇3-激酶抑制剂的三环杂环化合物

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1445742A1 (de) 1963-11-06 1968-12-19 Bayer Ag Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen
US4017500A (en) 1973-07-16 1977-04-12 Schering Corporation Certain 8-amino-1,7-naphthyridines
BE786081A (fr) 1971-07-13 1973-01-10 Uniroyal Sa Appareil et procede pour maintenir les tringles des bourrelets de pneu
US5703075A (en) 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
DE60039357D1 (de) 1999-08-03 2008-08-14 Lilly Icos Llc Pharmazeutische zusammensetzung enthaltend tadalafil
KR100774855B1 (ko) 2000-04-27 2007-11-08 아스텔라스세이야쿠 가부시키가이샤 축합 헤테로아릴 유도체
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
CA2414468A1 (en) 2000-06-30 2002-01-10 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
CA2491191C (en) 2002-07-15 2014-02-04 Exelixis, Inc. Receptor-type kinase modulators and methods of use
FR2846657B1 (fr) 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2005217320B2 (en) 2004-02-26 2011-07-21 Aska Pharmaceuticals Co., Ltd. Pyrimidine derivative
WO2005117889A1 (en) 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
NZ564065A (en) 2005-05-20 2011-03-31 Vertex Pharma Pyrrolopyridines useful as inhibitors of protein kinase
US20070208053A1 (en) 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
BRPI0710866A2 (pt) 2006-04-26 2012-08-14 Hoffmann La Roche compostos farmacÊuticos
KR101402474B1 (ko) 2006-04-26 2014-06-19 제넨테크, 인크. 포스포이노시티드 3-키나제 억제제 화합물 및 이를 포함하는 약학적 조성물
ATE510840T1 (de) 2006-06-26 2011-06-15 Ucb Pharma Sa Kondensierte thiazol-derivate als kinasehemmer
EP2441768A1 (en) 2006-11-13 2012-04-18 Eli Lilly & Co. Thienopyrimidinones for treatment of inflammatory disorders and cancers
AU2007334343A1 (en) 2006-12-15 2008-06-26 Ordway Research Institute, Inc. Treatments of therapy-resistant diseases comprising drug combinations
JP2010518014A (ja) 2007-01-31 2010-05-27 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用な２−アミノピリジン誘導体
US20100063032A1 (en) 2007-03-28 2010-03-11 Debenham John S Substituted pyrido[2,3-d]pyrimidine derivatives as cannabinoid-1 receptor modulators
JP2010529031A (ja) 2007-05-29 2010-08-26 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害剤としてのナフチリジン誘導体
GB0710528D0 (en) 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
CN101679456B (zh) * 2007-06-12 2012-09-05 霍夫曼-拉罗奇有限公司 噻唑并嘧啶类和它们作为磷脂酰肌醇3-激酶的抑制剂的应用
WO2008152394A1 (en) * 2007-06-12 2008-12-18 F.Hoffmann-La Roche Ag Pharmaceutical compounds
GB0721095D0 (en) * 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
WO2010015520A1 (de) 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh Substituierte naphthyridine und ihre verwendung als arzneimittel
WO2010037765A2 (en) 2008-10-03 2010-04-08 Merck Serono S.A. 4-morpholino-pyrido[3,2-d]pyrimidines
EP2459543B1 (en) 2009-07-29 2017-08-30 Karus Therapeutics Limited Benzo[e][1,3]oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors
US20110207736A1 (en) 2009-12-23 2011-08-25 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
GB201007347D0 (en) 2010-04-30 2010-06-16 Karus Therapeutics Ltd Compounds
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
CN105175396B (zh) 2011-07-27 2018-01-16 阿斯利康(瑞典)有限公司 取代的4‑甲氧基‑n3‑(嘧啶‑2‑基)苯‑1,3‑二胺化合物及其盐
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
WO2014081718A1 (en) 2012-11-20 2014-05-30 Genentech, Inc. Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
PL2994465T3 (pl) 2013-05-10 2019-01-31 Karus Therapeutics Limited Nowe inhibitory deacetylazy histonowej
BR112015029969A2 (pt) 2013-05-30 2017-07-25 Infinity Pharmaceuticals Inc tratamento de câncer usando moduladores de isoformas quinase pi3
EP3052494B1 (en) 2013-06-28 2018-12-26 H. Hoffnabb-La Roche Ag Azaindazole compounds as inhibitors of t790m containing egfr mutants
US9403779B2 (en) 2013-10-08 2016-08-02 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and either Her2 inhibitors or PI3K inhibitors
ES2818933T3 (es) 2013-10-10 2021-04-14 Acetylon Pharmaceuticals Inc Inhibidores de la HDAC en combinación con los inhibidores de la pi3k, para el tratamiento del linfoma no Hodgkin
GB201321730D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321729D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
MA40933A (fr) 2014-11-11 2017-09-19 Piqur Therapeutics Ag Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514756D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compound and method of use
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201909468D0 (en) 2019-07-01 2019-08-14 Karus Therapeutics Ltd Compounds for treating cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010052569A2 (en) * 2008-11-10 2010-05-14 University Of Basel Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes
CN102498115A (zh) * 2009-08-20 2012-06-13 卡鲁斯治疗有限公司 作为磷酸肌醇3-激酶抑制剂的三环杂环化合物

Also Published As

Publication number Publication date
US20200354378A1 (en) 2020-11-12
JP2017505343A (ja) 2017-02-16
EP3105233A1 (en) 2016-12-21
SMT201800280T1 (it) 2018-07-17
BR112016019462B1 (pt) 2023-02-07
KR20160127757A (ko) 2016-11-04
SI3105233T1 (sl) 2018-10-30
HRP20180768T1 (hr) 2018-08-10
MX2016010404A (es) 2016-11-30
CN106103450A (zh) 2016-11-09
IL247103A0 (en) 2016-09-29
BR112016019462B8 (pt) 2023-02-23
US20190092790A1 (en) 2019-03-28
BR112016019462A2 (enExample) 2017-08-15
WO2015121657A1 (en) 2015-08-20
DK3105233T3 (en) 2018-06-14
GB201402431D0 (en) 2014-03-26
MX370151B (es) 2019-12-03
US11708378B2 (en) 2023-07-25
NO3105233T3 (enExample) 2018-08-25
JP6516371B2 (ja) 2019-05-22
CA2939045C (en) 2022-09-13
IL247103B (en) 2020-03-31
PT3105233T (pt) 2018-06-15
RS57296B1 (sr) 2018-08-31
TR201807906T4 (tr) 2018-06-21
PL3105233T3 (pl) 2018-09-28
US10513530B2 (en) 2019-12-24
CY1120325T1 (el) 2019-07-10
AU2015216702B2 (en) 2018-11-08
US9981987B2 (en) 2018-05-29
US20160347771A1 (en) 2016-12-01
NZ723502A (en) 2019-05-31
CA2939045A1 (en) 2015-08-20
KR102491796B1 (ko) 2023-01-27
AU2015216702A1 (en) 2016-09-01
HUE037210T2 (hu) 2018-08-28
EP3105233B1 (en) 2018-03-28
SG11201606576UA (en) 2016-09-29
ZA201605586B (en) 2019-11-27
US20220041624A1 (en) 2022-02-10
LT3105233T (lt) 2018-06-25
ES2673278T3 (es) 2018-06-21

Similar Documents

Publication Publication Date Title
CN106103450B (zh) 作为磷酸肌醇3-激酶抑制剂的三环杂环化合物
CN114761398B (zh) 杂环rip1激酶抑制剂
CN108348505B (zh) 包含磷酸肌醇3-激酶抑制剂和第二抗增殖剂的组合物
CN112368278A (zh) Rip1抑制性化合物以及制备和使用其的方法
CN107207531B (zh) 作为TGF-β抑制剂的稠合的咪唑衍生物
CN104254532A (zh) 磷酸肌醇3-激酶抑制剂
CA2995902A1 (en) Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
JP2024542057A (ja) ２－（アリール－２－イル）モルホリンとその重水素化誘導体、製造方法及び応用
HK40065474A (en) Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent
WO2025049521A2 (en) Aryl ether analogs as inhibitors of the menin-mll interaction
HK1227870A1 (en) Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
HK1227870B (en) Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
HK40068242A (en) Rip1 inhibitory compounds and methods for making and using the same
HK40068242B (en) Rip1 inhibitory compounds and methods for making and using the same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20220824

Address after: Building 26, Lane 1000, Zhangheng Road, Pudong New Area, Shanghai

Patentee after: Fukang (Shanghai) Health Technology Co.,Ltd.

Address before: Oxfordshire

Patentee before: KARUS THERAPEUTICS Ltd.

TR01 Transfer of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Tricyclic heterocyclic compounds as phosphoinositol 3-kinase inhibitors

Effective date of registration: 20230301

Granted publication date: 20181211

Pledgee: Industrial Bank Co.,Ltd. Shanghai Putuo sub branch

Pledgor: Fukang (Shanghai) Health Technology Co.,Ltd.

Registration number: Y2023310000044

PE01 Entry into force of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right

Granted publication date: 20181211

Pledgee: Industrial Bank Co.,Ltd. Shanghai Putuo sub branch

Pledgor: Fukang (Shanghai) Health Technology Co.,Ltd.

Registration number: Y2023310000044

PC01 Cancellation of the registration of the contract for pledge of patent right